WST

West Pharmaceutical Services Inc. Healthcare - Medical Supplies Investor Relations →

NO
9.6% ABOVE
↓ Approaching Was 9.9% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $299.20
14-Week RSI 78
Rel. Volume (14w) This week's trading vs. the 14-week average 1.0x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.01

West Pharmaceutical Services Inc. (WST) closed at $327.95 as of 2026-06-19, trading 9.6% above its 200-week moving average of $299.20. The stock is currently moving closer to the line, down from 9.9% last week. With a 14-week RSI of 78, WST is in overbought territory.

Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.01 ratio) is neutral — neither side is clearly dominating.

Over the past 2365 weeks of data, WST has crossed below its 200-week moving average 24 times. On average, these episodes lasted 20 weeks. Historically, investors who bought WST at the start of these episodes saw an average one-year return of +29.2%.

With a market cap of $23.2 billion, WST is a large-cap stock. The company generates a free cash flow yield of 1.2%. Return on equity stands at 19.1%, a solid level. The stock trades at 7.8x book value.

WST is a Dividend Aristocrat, having increased its dividend for 25 or more consecutive years. The current yield is 27.00%. Management has been repurchasing shares, with a 2.8% reduction over three years. WST passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.

Over the past 33.5 years, a hypothetical investment of $100 in WST would have grown to $9354, compared to $3097 for the S&P 500. That represents an annualized return of 14.5% vs 10.8% for the index — confirming WST as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: WST vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After WST Crosses Below the Line?

Across 16 historical episodes, buying WST when it crossed below its 200-week moving average produced an average return of +21.4% after 12 months (median +21.0%), compared to +20.3% for the S&P 500 over the same periods. 80% of those episodes were profitable after one year. After 24 months, the average return was +40.7% vs +40.9% for the index.

Each line shows $100 invested at the moment WST crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices WST would reach each dislocation threshold.

Current Bean Score -1.37σ
Current FCF Yield 2.06%
Baseline Yield 2.55%
Historical σ 0.36pp

Dislocation Price Levels

Prices where WST's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-23.

LevelσPriceSignal
Deep Value+2σ$197.63Unusually cheap — potential buy zone
Value+1σ$222.12Cheap vs. own history
Fair Value+0σ$253.52Historical mean behavior
Expensive-1σ$295.28Expensive vs. own history
Deep Expensive-2σ$353.50Unusually expensive — potential trim zone

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Data depth: 2 quarterly baselines, 22 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

11 / 13 weeks minimum

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from WST's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

Yield Dislocation -0.61σ Dividend yield vs own 10-yr norm
Drawdown Score +0.58σ Distance from line vs own history
Sector-Relative N/A Vs sector median this week
Buyback Acceleration +0.5pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History -0.7pp Vs own recent annual mean
Earnings Quality Improving Accrual gap trend (-5.4pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Advertisement

Historical Touches

WST has crossed below its 200-week MA 24 times with an average 1-year return of +29.2% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Aug 1982Aug 198210.1%+111.7%+36889.9%
Jul 1984Feb 19852913.6%+55.4%+27309.7%
Apr 1985Apr 198511.8%+50.3%+23564.3%
Nov 1987Dec 198715.8%+14.0%+18138.4%
Mar 1988May 1988712.2%+23.7%+17063.0%
Jul 1988Jul 198810.1%+37.1%+16278.8%
Aug 1988Dec 19882011.3%+56.6%+16725.5%
Aug 1990Apr 19913433.5%+7.1%+13902.9%
May 1991May 199131.8%+37.3%+14024.2%
Dec 1995Jan 199642.6%+27.3%+8607.0%
Feb 1996May 1996136.0%+26.4%+8467.6%
Jul 1996Aug 199610.1%+25.5%+8109.3%
Aug 1998Sep 199823.0%+47.7%+6992.0%
Feb 2000Feb 200210432.0%-7.8%+6306.3%
Jul 2002May 20034236.0%+2.1%+6626.5%
Jun 2003Jun 200321.8%+74.1%+6881.8%
Nov 2008Aug 20093923.7%+8.5%+2000.8%
Nov 2009Nov 200942.8%+4.7%+1836.3%
Dec 2009Mar 2010119.3%+9.5%+1795.1%
May 2010Dec 20102916.3%+17.5%+1746.2%
Aug 2011Oct 201173.7%+26.1%+1779.3%
Nov 2011Jan 201297.1%+37.8%+1797.8%
Sep 2022Jan 20231816.9%+46.9%+30.4%
May 2024Apr 202610040.2%-37.8%-0.5%
Average20+29.2%

Frequently Asked Questions

Is WST below its 200-week moving average?

No. West Pharmaceutical Services Inc. (WST) is currently 9.6% above its 200-week moving average of $299.20. It would need to fall to $299.20 to cross below the line.

What is WST's 200-week moving average price?

West Pharmaceutical Services Inc.'s 200-week moving average is $299.20 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when WST drops below its 200-week moving average?

WST has crossed below its 200-week moving average 24 times in our data. On average, buying at that moment produced a one-year return of +29.2%. These dips have historically been decent entry points. These episodes lasted 20 weeks on average.

Is WST a good value right now?

Here's what our data says about WST as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 78 (overbought). Free cash flow yield is 1.2%. Return on equity is 19.1%. Price-to-book is 7.8x. This is not a buy or sell recommendation — always do your own research.

How does WST compare to the S&P 500?

Over the past 33.5 years, $100 invested in WST would have grown to $9354, compared to $3097 for the S&P 500. That's 14.5% annualized vs 10.8% for the index. WST has outperformed the broader market over this period.

Does WST pay a dividend?

Yes. West Pharmaceutical Services Inc. currently pays a dividend yield of 27.00%. It is also a Dividend Aristocrat, meaning it has raised its dividend for 25 or more consecutive years.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-06-19